# Plain Language Summary of H.R. 7827

This bill is designed to speed up the development of vaccines that could help treat or prevent addiction to opioids, cocaine, methamphetamine, and alcohol. Right now, these addictions are major public health problems, and the bill essentially puts a financial incentive and regulatory fast-track in place to encourage pharmaceutical companies to research and develop these vaccines.

The bill does two main things. First, it gives special treatment to any vaccine for these addictions that goes through the FDA approval process. Specifically, any company developing such a vaccine can get it labeled as a "breakthrough therapy" and a "fast track product," which means the FDA will review it more quickly than normal drugs. This could cut years off the development timeline. The bill also requires the FDA to give "priority review" to these applications, meaning they get bumped to the front of the line. All of these speed-ups last for 10 years from when the bill becomes law.

Second, the bill creates a $1 billion prize—called the Vaccine X-Prize—that goes to the first company that successfully develops, gets FDA approval for, and mass-produces a vaccine for one of these four addictions. This is a one-time award, so only the first company to cross the finish line gets the money. The idea is that this combination of faster approval and a huge financial reward will motivate companies to invest in research that they might otherwise skip over because addiction treatment vaccines are risky and expensive to develop.

In practical terms, if this bill passes, people struggling with addiction might eventually have access to a new type of treatment option, and companies have a clearer financial reason to take on the challenge of developing these vaccines. However, the bill doesn't guarantee that such vaccines will actually work or be developed—it just removes some of the barriers and adds financial incentives to try.

To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.